Literature DB >> 10325766

Interferon alpha treatment of molluscum contagiosum in immunodeficiency.

J Hourihane1, E Hodges, J Smith, M Keefe, A Jones, G Connett.   

Abstract

A sister (aged 6 years) and brother (aged 8 years) presented four months apart with severe molluscum contagiosum. Both children demonstrated clinical and laboratory evidence of combined immunodeficiency. The extent of skin involvement by molluscum contagiosum precluded conventional treatment as well as intralesional interferon alpha (IFN alpha). Both subjects responded well to subcutaneous IFN alpha.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10325766      PMCID： PMC1717791          DOI： 10.1136/adc.80.1.77

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  9 in total

1.  Molluscum contagiosum in patients with human immunodeficiency virus infection. A review of twenty-seven patients.

Authors:  J J Schwartz; P L Myskowski
Journal:  J Am Acad Dermatol       Date:  1992-10       Impact factor: 11.527

2.  Photoaccentuated erythroderma associated with CD4+ T lymphocytopenia: successful treatment with 5-methoxypsoralen and UVA, interferon alfa-2b, and extracorporeal photopheresis.

Authors:  P Wolf; R Müllegger; L Cerroni; R Aigner; G Fueger; G Höfler; J Derbaschnig; H Kerl
Journal:  J Am Acad Dermatol       Date:  1996-08       Impact factor: 11.527

3.  Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir.

Authors:  C B Hicks; S A Myers; J Giner
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

Review 4.  Protracted cutaneous disorders in association with low CD4+ lymphocyte counts.

Authors:  H A Kurwa; R Marks
Journal:  Br J Dermatol       Date:  1995-10       Impact factor: 9.302

5.  Intralesional interferon for the treatment of recalcitrant molluscum contagiosum in HIV antibody positive individuals--a preliminary report.

Authors:  M R Nelson; S Chard; S E Barton
Journal:  Int J STD AIDS       Date:  1995 Sep-Oct       Impact factor: 1.359

6.  Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.

Authors:  C Barbera; F Bortolotti; C Crivellaro; A Coscia; L Zancan; P Cadrobbi; G Nebbia; M N Pillan; L Lepore; T Parrella
Journal:  Hepatology       Date:  1994-08       Impact factor: 17.425

7.  Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection.

Authors:  P Vajro; M Tedesco; A Fontanella; A De Vincenzo; R Vecchione; R Ammendola; L M Terracciano; A Novissimo; A Vegnente
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129

8.  Interferon treatment in children with chronic hepatitis B.

Authors:  M Ruíz-Moreno
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083

9.  Alpha-interferon (Wellferon) as an adjunct to standard surgical therapy in the management of recurrent respiratory papillomatosis.

Authors:  B N Benjamin; P A Gatenby; R Kitchen; H Harrison; K Cameron; A Basten
Journal:  Ann Otol Rhinol Laryngol       Date:  1988 Jul-Aug       Impact factor: 1.547
  9 in total
  3 in total

1.  Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001.

Authors:  Jeffrey I Cohen; Wilmer Davila; Mir A Ali; Siu-Ping Turk; Edward W Cowen; Alexandra F Freeman; Kening Wang
Journal:  J Infect Dis       Date:  2012-01-19       Impact factor: 5.226

Review 2.  [Mollusca contagiosa. From paediatric dermatology to sexually transmitted infection].

Authors:  M Skerlev; K Husar; M Sirotković-Skerlev
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

Review 3.  Non-HPV Perianal and Anorectal Sexually Transmitted Viral Infections.

Authors:  Margarita Murphy; Gabriel Ryan Chedister; Virgilio George
Journal:  Clin Colon Rectal Surg       Date:  2019-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.